Publication:
The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome

dc.contributor.authorYILDIZHAN, BEGÜM
dc.contributor.authorANIK İLHAN, GÖKÇE
dc.contributor.authorPEKİN, TANJU
dc.contributor.authorsIlhan, Gokce Anik; Yildizhan, Begum; Pekin, Tanju
dc.date.accessioned2022-03-12T22:29:20Z
dc.date.accessioned2026-01-11T15:43:09Z
dc.date.available2022-03-12T22:29:20Z
dc.date.issued2019
dc.description.abstractThis study was performed to assess the impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal, and metabolic parameters in lean women with PCOS. Retrospective analysis of 120 consecutive lean PCOS subjects was performed. Subjects were divided into two groups according to HOMA-IR, as IR + and IR-. A HOMA-IR value above 2.5 was used to indicate IR. Clinical, hormonal and metabolic parameters were compared between the two groups. Correlations between LAP and VAI and clinical, hormonal, metabolic features in women PCOS were analyzed. One hundred twenty lean PCOS subjects were enrolled, of which 39 were insulin resistant. Comparison of group means showed significantly higher values for TG levels, FAI, FGS, TG/HDL-c, TyG, LAP, and VAI indexes and lower values for glucose/insulin ratio and QUICKI in the IR + group. LAP and VAI were both found to be positively correlated with each other and with WC, FAI, FGS, TG, TC levels, lipid ratios, TyG index, and HOMA-IR and negatively correlated with Glucose/Insulin ratio, QUICKI, and HDL-c in lean women with PCOS. LAP and VAI may be promising in early identification of IR and cardiometabolic risk and may be useful for the assessment of hyperandrogenism in lean women with PCOS.
dc.identifier.doi10.1080/09513590.2018.1519794
dc.identifier.eissn1473-0766
dc.identifier.issn0951-3590
dc.identifier.pubmed30303693
dc.identifier.urihttps://hdl.handle.net/11424/235369
dc.identifier.wosWOS:000462468300011
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofGYNECOLOGICAL ENDOCRINOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPolycystic ovary syndrome
dc.subjectlean
dc.subjectinsulin resistance
dc.subjectlipid accumulation product
dc.subjectvisceral adiposity index
dc.subjectINSULIN-RESISTANCE
dc.subjectCARDIOVASCULAR RISK
dc.subjectSENSITIVITY
dc.subjectPOPULATION
dc.subjectPREDICTORS
dc.subjectSEVERITY
dc.subjectMARKERS
dc.titleThe impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage236
oaire.citation.issue3
oaire.citation.startPage233
oaire.citation.titleGYNECOLOGICAL ENDOCRINOLOGY
oaire.citation.volume35

Files